Tumor necrosis factor: how to improve the antitumor activity and decrease accompanying side effects for therapeutic application.

Haranaka, K

Haranaka, K.

Affiliation

Haranaka K; Department of Internal Medicine, University of Tokyo, Japan.

J Biol Response Mod ; 7(6): 525-34, 1988 Dec.

Article in En | MEDLINE | ID: mdl-3063778

Subject(s)

Antineoplastic Agents; Tumor Necrosis Factor-alpha/therapeutic use; Animals; Clinical Trials as Topic; Endothelium, Vascular/cytology; Endothelium, Vascular/drug effects; Lipid Peroxidation/drug effects; Lysosomes/enzymology; Models, Biological; Oxygen/physiology; Recombinant Proteins/therapeutic use; Tumor Necrosis Factor-alpha/adverse effects; Tumor Necrosis Factor-alpha/pharmacology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor-alpha / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Biol Response Mod Year: 1988 Document type: Article Affiliation country: Japan Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links